MiNK Therapeutics, Inc. (INKT)
NASDAQ: INKT · Real-Time Price · USD
10.88
-0.26 (-2.33%)
At close: Apr 28, 2026, 4:00 PM EDT
11.09
+0.21 (1.93%)
After-hours: Apr 28, 2026, 7:40 PM EDT
MiNK Therapeutics Employees
MiNK Therapeutics had 23 employees as of December 31, 2024. The number of employees decreased by 8 or -25.81% compared to the previous year.
Employees
23
Change (1Y)
-8
Growth (1Y)
-25.81%
Revenue / Employee
n/a
Profits / Employee
-$543,229
Market Cap
54.03M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 23 | -8 | -25.81% |
| Dec 31, 2023 | 31 | -6 | -16.22% |
| Dec 31, 2022 | 37 | 4 | 12.12% |
| Dec 31, 2021 | 33 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Metagenomi Therapeutics | 119 |
| MindWalk Holdings | 102 |
| Cue Biopharma | 29 |
| PDS Biotechnology | 24 |
| Entera Bio | 22 |
| iBio, Inc. | 20 |
| Atossa Therapeutics | 16 |
| Instil Bio | 14 |
INKT News
- 25 days ago - MiNK Therapeutics and Memorial Sloan Kettering to Present Phase II Study of agenT-797 Combination in PD-1 Refractory Gastroesophageal Cancer at AACR 2026 - GlobeNewsWire
- 27 days ago - MiNK Therapeutics Announces Abstract Acceptance for Presentation at the American Thoracic Society (ATS) 2026 International Conference - GlobeNewsWire
- 4 weeks ago - MiNK Therapeutics Earnings Call Transcript: Q4 2025 - Transcripts
- 4 weeks ago - MiNK Therapeutics Reports Q4 and Full Year 2025 Results; Phase 2 Programs Advance with Impactful Non-Dilutive Momentum - GlobeNewsWire
- 6 weeks ago - MiNK Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Highlight Platform Expansion Across iNKT Cell Therapy Programs - GlobeNewsWire
- 6 weeks ago - Why Is MiNK Therapeutics Stock Trading Lower On Wednesday? - Benzinga
- 7 weeks ago - MiNK Therapeutics Pediatric Cancer Breakthrough Sparks Stock Rally - Benzinga
- 7 weeks ago - MiNK Therapeutics Announces Collaboration with C-Further to Advance PRAME-Targeted iNKT Cell Therapy for Pediatric Cancers - GlobeNewsWire